Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Merrimack Pharmaceuticals Inc
(NQ:
MACK
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
-
Bid (Size)
15.15 (8)
Ask (Size)
15.16 (1)
Prev. Close
15.13
Today's Range
N/A - N/A
52wk Range
12.54 - 15.89
Shares Outstanding
14,400,000
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
MACK Stock Earnings: Merrimack Pharmaceuticals Reported Results for Q1 2024
May 16, 2024
Merrimack Pharmaceuticals just reported results for the first quarter of 2024.
Via
InvestorPlace
Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock
May 10, 2024
From
Merrimack Pharmaceuticals, Inc.
Via
Business Wire
Performance
More News
Read More
Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of Dissolution
May 09, 2024
From
Merrimack Pharmaceuticals, Inc.
Via
Business Wire
Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution
April 30, 2024
From
Merrimack Pharmaceuticals, Inc.
Via
Business Wire
Merrimack Receives $225 Million Milestone Payment from Ipsen
March 27, 2024
From
Merrimack Pharmaceuticals, Inc.
Via
Business Wire
Merrimack Pharmaceuticals Inc. (NASDAQ: MACK) Highlighted for Surprising Price Action
March 25, 2024
Via
Investor Brand Network
MACK Stock Earnings: Merrimack Pharmaceuticals Reported Results for Q4 2023
March 08, 2024
Via
InvestorPlace
Merrimack Reports Full Year 2023 Financial Results
March 07, 2024
From
Merrimack Pharmaceuticals, Inc.
Via
Business Wire
Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
February 13, 2024
From
Merrimack Pharmaceuticals, Inc.
Via
Business Wire
$2M Bet On Ford? Check Out These 4 Stocks Insiders Are Buying
December 12, 2023
Via
Benzinga
Merrimack Reports Third Quarter 2023 Financial Results
November 02, 2023
From
Merrimack Pharmaceuticals, Inc.
Via
Business Wire
Pancreatic Cancer Battle Boosted by $200M VC Firm
September 19, 2023
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
Merrimack Reports Second Quarter 2023 Financial Results
August 03, 2023
From
Merrimack Pharmaceuticals, Inc.
Via
Business Wire
Merrimack Reports First Quarter 2023 Financial Results
May 04, 2023
From
Merrimack Pharmaceuticals, Inc.
Via
Business Wire
Why Jounce Therapeutics Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket
March 15, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
March 15, 2023
Via
InvestorPlace
Luna Innovations, Guess? And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
March 15, 2023
Via
Benzinga
Merrimack Reports Full Year 2022 Financial Results
March 09, 2023
From
Merrimack Pharmaceuticals, Inc.
Via
Business Wire
3 Stocks Insiders Are Buying: Triumph Financial And More
February 01, 2023
Via
Benzinga
$2.6M Bet On This Energy Stock? Check Out These 3 Stocks Insiders Are Buying
January 18, 2023
Via
Benzinga
Insiders Buying Heska, B. Riley Financial And 2 Other Stocks
January 10, 2023
Via
Benzinga
$1.4 Million Bet On Joint Corp? Check Out These 3 Stocks Insiders Are Buying
January 04, 2023
Via
Benzinga
Merrimack Pharmaceuticals Extends Section 382 Net Operating Loss Rights Plan
December 05, 2022
From
Merrimack Pharmaceuticals, Inc.
Via
Business Wire
Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic Cancer
November 15, 2022
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
Biotechs with Evolving Therapies Have Potential to Revolutionize Treatments for Pancreatic Cancer
November 10, 2022
Via
FinancialNewsMedia
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
